Two Talks to Highlight Chemistry Department 50th Anniversary Chemistry & New Neuroscience Major

The three-part series of talks by Washington College Chemistry Alumni, who have distinguished themselves in post-college careers at the interface of chemistry and the health sciences, ends with back-to back presentations, on March 31, 2022, by John L. Musachio ’87, Ph.D. of the National Institutes of Health, and on April 7, 2022, by Matthew S. Streeter ’13, Ph.D. of Entrada Therapeutics. Both presentations will be held in Litrenta Lecture Hall of the John S. Toll Science Center on the Washington College Campus.

The 4:30 PM presentation on March 31, 2022, by Dr. Musachio, “My PET Projects at NIH” will focus on his work and that of his 6-person team at NIH, where he is Head of the Production and Quality Control Section. Dr. Musachio, a Magna cum Laude graduate of Washington College, with a major in Chemistry and winner of the Joseph H. McLain Prize, received a Ph.D. in Radiochemistry from The Johns Hopkins University, where he started his career as Research Associate moving quickly to tenure-track positions, first as Instructor then as Assistant Professor.  In 2002 he left JHU to join the new molecular imaging branch at the National Institutes of Health to establish a new radiochemistry laboratory.  In 2004 he moved to the PET (Positron Emission Tomography) department at the NIH Clinical Center.  Dr. Musachio, a member of the Alpha of Maryland Chapter of Phi Beta Kappa, is author or co-author of over 60 peer-reviewed articles in the field of Neuroscience.

The 5:00 PM talk, on April 7, 2022, by Dr. Streeter, “Novel Approaches to Engage Targets Previously Considered Inaccessible and Undruggable” will follow a ceremony of induction for new members of Gamma Sigma Epsilon, a National Chemistry Honor Society.

Dr. Streeter, a Magna cum Laude graduate of Washington College, with a double major in Chemistry and Psychology and winner of the Joseph H. McLain Prize, received a Ph.D. in Chemistry from Yale University. He was awarded a Post-doctoral Fellowship at Dana-Farber Cancer Institute at Harvard Medical School.

Dr. Streeter’s presentation will focus of the work of Entrada Therapeutics, which, using their proprietary Endosomal Escape Vehicle (EEVTM),  has developed a series of conjugated oligonucleotides, conjugated enzymes, and conjugated antibodies that have shown to have the ability to fundamentally improve the standard of care across a wide range of neurological diseases.

Photo Courtesy of Dr. Frank Creegan

Leave a Reply

Your email address will not be published. Required fields are marked *